Review Article

What lessons can be learned from the launch of generic clopidogrel?

Published in: Volume 1 / Year 2012 / Issue 2
Author(s): ,
Page: 58-68

Author byline as per print journal: Christoph Baumgärtel1, MD; Brian Godman2,3,4, BSc, PhD; Rickard E Malmstrom5, MD, PhD; Morten Andersen6, MD, PhD; Mohammed Abuelkhair7, PharmD; Shajahan Abdu7, MD; Marion Bennie8,9, MSc;… Read More »

A review of patient perspectives on generics substitution: what are the challenges for optimal drug use

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 28-32

Author byline as per print journal: Helle Håkonsen, MScPharm, PhD; Else-Lydia Toverud, MScPharm, PhD Introduction: With a few exceptions, generic drug use has been promoted in western countries by allowing pharmacists to… Read More »

European payer initiatives to reduce prescribing costs through use of generics

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 22-7

Author byline as per print journal:  Brian Godman1,2,3, BSc, PhD; Bjorn Wettermark1,4, MSc, PhD; Iain Bishop5, BSc; Thomas Burkhardt6, MSc; Jurij Fürst7, PhD; Kristina Garuoliene8, MD; Ott Laius9, MScPharm; Jaana E Martikainen10,… Read More »

A patient-centred paradigm for the biosimilars market

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 17-21

Abstract: The advent of similar biological medicinal products or ‘biosimilars’ in Europe in the 2000s has led to development of a global biosimilars market and regulatory frameworks designed specifically for… Read More »

Biologicals and biosimilars: a review of the science and its implications

Published in: Volume 1 / Year 2012 / Issue 1
Author(s):
Page: 13-6

Abstract: Biopharmaceuticals are medicines whose active drug substance is made by living cells. Copies of these drugs, called biosimilars, are not identical to their reference drug and therefore specific regulatory… Read More »

A review of generic medicine pricing in Europe

Published in: Volume 1 / Year 2012 / Issue 1
Author(s):
Page: 08-12

Introduction: Switching from originator products to generic equivalents is a key method used by governments to reduce costs and keep their healthcare systems sustainable. The aim of this article is… Read More »

A critical review of substitution policy for biosimilars in Canada

Published in: Volume 10 / Year 2021 / Issue 3
Author(s): ,

Canada has approved a total of 36 biosimilars. While the approval of biosimilars is regulated at the national level, decisions about biosimilar substitution are made at the provincial level. Four… Read More »

Microbiological, scientific and regulatory perspectives of hand sanitizers

Published in: Volume 10 / Year 2021 / Issue 3

Author byline as per print journal: Adjunct Associate Professor Sia Chong Hock, BSc Pharm, MSc; Tan Ying Ting, BSc Pharm (Hons); Associate Professor Chan Lai Wah, BSc Pharm (Hons), PhD… Read More »

Page 5 of 5 « Previous1 2 3 4 5
Go Back Print